Spartalizumab Safety for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to ensure that spartalizumab remains safe and tolerable for patients who are already using it. The medication helps the immune system fight cancer, and the study ensures patients can keep accessing it safely.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It seems focused on participants already receiving spartalizumab, so it's best to ask the study team for details.
Is Spartalizumab safe for humans?
What makes the drug Spartalizumab unique for cancer treatment?
Spartalizumab is unique because it is a monoclonal antibody that targets PD-1, a protein on immune cells, to help the immune system attack cancer cells. When combined with Sabatolimab, which targets TIM-3, it offers a novel approach by blocking two different pathways that tumors use to evade the immune system, potentially enhancing the antitumor response.12345
What data supports the effectiveness of the drug Spartalizumab for cancer?
Research shows that Spartalizumab, when used alone or with Sabatolimab, has shown preliminary effectiveness in treating advanced solid tumors, with some patients experiencing partial tumor shrinkage. Additionally, Sabatolimab has shown promise in enhancing the immune response against cancer cells in other conditions, suggesting potential benefits when combined with Spartalizumab.12346
Who Is on the Research Team?
Novartis Pharmaceuticals
Principal Investigator
Novartis Pharmaceuticals
Are You a Good Fit for This Trial?
This trial is for patients already participating in a Novartis-sponsored study, receiving spartalizumab alone or with other treatments for solid tumors. They must be benefiting from the treatment as judged by their doctor and meet all other ongoing study requirements.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants continue to receive spartalizumab as a single agent or in combination with other study treatments
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Spartalizumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD